Kirstetter M - Search Results

1

Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.

Wirden M, Marcelin AG, Simon A, Kirstetter M, Tubiana R, Valantin MA, Paris L, Bonmarchand M, Conan F, Kalkias L, Katlama C, Calvez V. Wirden M, et al. Among authors: kirstetter m. J Med Virol. 2005 Jul;76(3):297-301. doi: 10.1002/jmv.20359. J Med Virol. 2005. PMID: 15902696

2

Long-term virological outcome in patients infected with multi-nucleoside analogue-resistant HIV-1.

Clevenbergh P, Kirstetter M, Liotier JY, Dupon M, Philibert P, Jacomet C, Cua E, Montagne N, Schmit JC, Dellamonica P. Clevenbergh P, et al. Among authors: kirstetter m. Antivir Ther. 2002 Dec;7(4):305-8. Antivir Ther. 2002. PMID: 12553486

3

Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.

Clevenbergh P, Boulmé R, Kirstetter M, Dellamonica P. Clevenbergh P, et al. Among authors: kirstetter m. HIV Med. 2004 Jul;5(4):284-8. doi: 10.1111/j.1468-1293.2004.00222.x. HIV Med. 2004. PMID: 15236618 Free article. Clinical Trial.

4

Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution.

Wirden M, Malet I, Derache A, Marcelin AG, Roquebert B, Simon A, Kirstetter M, Joubert LM, Katlama C, Calvez V. Wirden M, et al. Among authors: kirstetter m. AIDS. 2005 Mar 24;19(6):630-2. doi: 10.1097/01.aids.0000163942.93563.fd. AIDS. 2005. PMID: 15802984

5

Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study.

De Truchis P, Kirstetter M, Perier A, Meunier C, Zucman D, Force G, Doll J, Katlama C, Rozenbaum W, Masson H, Gardette J, Melchior JC. De Truchis P, et al. Among authors: kirstetter m. J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):278-85. doi: 10.1097/QAI.0b013e31802c2f3d. J Acquir Immune Defic Syndr. 2007. PMID: 17179770 Clinical Trial.

6

Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia.

Katlama C, Soulié C, Caby F, Denis A, Blanc C, Schneider L, Valantin MA, Tubiana R, Kirstetter M, Valdenassi E, Nguyen T, Peytavin G, Calvez V, Marcelin AG. Katlama C, et al. Among authors: kirstetter m. J Antimicrob Chemother. 2016 Sep;71(9):2646-50. doi: 10.1093/jac/dkw186. Epub 2016 Jun 10. J Antimicrob Chemother. 2016. PMID: 27287235

7

Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study.

Valantin MA, Durand L, Wirden M, Assoumou L, Caby F, Soulié C, Nguyen TT, Tubiana R, Kirstetter M, Junot H, Marcelin AG, Peytavin G, Tilleul P, Katlama C. Valantin MA, et al. Among authors: kirstetter m. J Antimicrob Chemother. 2019 Sep 1;74(9):2716-2722. doi: 10.1093/jac/dkz255. J Antimicrob Chemother. 2019. PMID: 31273376

8

A highly virulent variant of HIV-1 circulating in the Netherlands.

Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C; Netherlands ATHENA HIV Observational Cohort†; BEEHIVE Collaboration†. Wymant C, et al. Science. 2022 Feb 4;375(6580):540-545. doi: 10.1126/science.abk1688. Epub 2022 Feb 3. Science. 2022. PMID: 35113714 Free article.

9

Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH).

Barré T, Zucman D, Marcellin F, Ramier C, Protopopescu C, Tardieu R, Ory K, Salmon-Céron D, Carrieri P; ANRS CO13 HEPAVIH Study Group. Barré T, et al. J Viral Hepat. 2023 Nov;30(11):897-900. doi: 10.1111/jvh.13865. Epub 2023 Jun 26. J Viral Hepat. 2023. PMID: 37357886 No abstract available.

10

HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome.

Boccara F, Mary-Krause M, Potard V, Teiger E, Lang S, Hammoudi N, Chauvet M, Ederhy S, Dufour-Soulat L, Ancedy Y, Nhan P, Adavane S, Steg PG, Funck-Brentano C, Costagliola D, Cohen A; PACS‐HIV (Prognosis of Acute Coronary Syndrome in HIV‐Infected Patients) Investigators †. Boccara F, et al. J Am Heart Assoc. 2020 Sep;9(17):e017578. doi: 10.1161/JAHA.119.017578. Epub 2020 Aug 26. J Am Heart Assoc. 2020. PMID: 32844734 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page